Healthcare provider profile · identity verified

Sarah B Schlie, DO

Allopathic & Osteopathic Physicians|Family Medicine · FORT WAYNE, IN · NPI 1164650628

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Sarah B Schlie, DO received $18.59 in general payments during 2025 across 1 reported records.

Immunocore Limited accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$18.59

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Immunocore Limited Unresolved — no canonical attribution shown $18.59100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$18.591

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
KIMMTRAK
Normalized: kimmtrak
Drug Immunocore Limited $18.59 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Levothyroxine SodiumLevothyroxine Sodium33188
Atorvastatin CalciumAtorvastatin Calcium21867
LisinoprilLisinopril15545
Losartan PotassiumLosartan Potassium13635
Amlodipine BesylateAmlodipine Besylate12238
OmeprazoleOmeprazole12037
HydrochlorothiazideHydrochlorothiazide11735
MeloxicamMeloxicam10928
Metformin HclMetformin Hcl9528
Pantoprazole SodiumPantoprazole Sodium9329
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide8824
Metoprolol SuccinateMetoprolol Succinate8222
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide7722
Albuterol Sulfate HfaAlbuterol Sulfate7432
GabapentinGabapentin7326
Rosuvastatin CalciumRosuvastatin Calcium7222
Sertraline HclSertraline Hcl6920
FamotidineFamotidine6620
Liothyronine SodiumLiothyronine Sodium6517
Bupropion XlBupropion Hcl5820
Duloxetine HclDuloxetine Hcl5712
Trazodone HclTrazodone Hcl5517
Citalopram HbrCitalopram Hydrobromide5416
CarvedilolCarvedilol5315
Cyclobenzaprine HclCyclobenzaprine Hcl4317
PrednisonePrednisone4330
SimvastatinSimvastatin4311
Fluticasone PropionateFluticasone Propionate4214
SynthroidLevothyroxine Sodium42suppressed
Montelukast SodiumMontelukast Sodium4112
Metoprolol TartrateMetoprolol Tartrate4012
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen39suppressed
AllopurinolAllopurinol3711
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36suppressed
Metformin Hcl ErMetformin Hcl36suppressed
AzithromycinAzithromycin3432
Venlafaxine Hcl ErVenlafaxine Hcl32suppressed
AtenololAtenolol31suppressed
Fluoxetine HclFluoxetine Hcl31suppressed
Pravastatin SodiumPravastatin Sodium31suppressed
Buspirone HclBuspirone Hcl3011
Tramadol HclTramadol Hcl30suppressed
SymbicortBudesonide/Formoterol Fumarate29suppressed
Tamsulosin HclTamsulosin Hcl29suppressed
Olmesartan MedoxomilOlmesartan Medoxomil27suppressed
Potassium ChloridePotassium Chloride27suppressed
Armour ThyroidThyroid,pork26suppressed
Bupropion Hcl SrBupropion Hcl26suppressed
Ondansetron OdtOndansetron2615
OzempicSemaglutide26suppressed
Tizanidine HclTizanidine Hcl26suppressed
Zolpidem TartrateZolpidem Tartrate26suppressed
AlprazolamAlprazolam25suppressed
Paroxetine HclParoxetine Hcl23suppressed
CephalexinCephalexin2217
EzetimibeEzetimibe22suppressed
JardianceEmpagliflozin22suppressed
SpironolactoneSpironolactone21suppressed
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid21suppressed
Eletriptan HbrEletriptan Hydrobromide20suppressed
GlimepirideGlimepiride20suppressed
LantusInsulin Glargine,hum.Rec.Anlog20suppressed
MounjaroTirzepatide20suppressed
ClonazepamClonazepam19suppressed
FurosemideFurosemide19suppressed
Amitriptyline HclAmitriptyline Hcl18suppressed
JanuviaSitagliptin Phosphate16suppressed
Triamcinolone AcetonideTriamcinolone Acetonide1611
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide16suppressed
ChlorthalidoneChlorthalidone15suppressed
Escitalopram OxalateEscitalopram Oxalate15suppressed
Esomeprazole MagnesiumEsomeprazole Magnesium14suppressed
Humalog Kwikpen U-100Insulin Lispro14suppressed
Memantine HclMemantine Hcl14suppressed
PregabalinPregabalin14suppressed
EliquisApixaban13suppressed
Hydroxyzine HclHydroxyzine Hcl13suppressed
Oxybutynin Chloride ErOxybutynin Chloride13suppressed
RisperidoneRisperidone13suppressed
ValacyclovirValacyclovir Hcl13suppressed
CefdinirCefdinir1212
ClopidogrelClopidogrel Bisulfate12suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12suppressed
HumalogInsulin Lispro12suppressed
NystatinNystatin12suppressed
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12suppressed
Easy Touch Alcohol Prep PadsAlcohol Antiseptic Pads11suppressed
Estradiol (Once Weekly)Estradiol11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $18.59 · 1 records Immunocore Limited KIMMTRAK
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error